Patents
Literature
4 results about "Peak plasma" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The maximum (peak) plasma drug concentration is the highest level of drug that occurs in the plasma portion of blood after administration of the drug. Another way to say this is that peak plasma concentrations of any drug occurs when the elimination rate equals the rate of absorption.
Cancer treatment using docetaxel by controlling peak plasma levels
Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.
Owner:MODRA PHARMACEUTICALS B V
Use of higher doses of modified release huperzine formulations
PendingUS20260076910A1Organic active ingredientsNervous disorderImmediate releasePharmaceutical drug
The present application discloses pharmaceutical compositions and methods of treating neurological disorders and seizure disorders with the high dose modified release compositions of huperzine. The pharmaceutical compositions and methods described herein, allow for higher dosing of huperzine, while avoiding rapid peak plasma levels, thereby avoiding the dose-limiting adverse events associated with the immediate release formulations.
Owner:BISCAYNE NEUROTHERAPEUTICS INC
Use of terazosin or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the prevention and / or treatment of liver fibrosis
This invention provides the use of terazosin or its pharmaceutically acceptable salts in the preparation of medicaments for the prevention and / or treatment of liver fibrosis, relating to the field of biomedical technology. This invention is the first to discover that terazosin or its pharmaceutically acceptable salts can be used to prevent and treat liver fibrosis. It reveals that terazosin or its pharmaceutically acceptable salts can improve the degree of liver fibrosis by improving liver function, reducing the content of α-SMA (a marker of activated hepatic stellate cells) in liver tissue, reducing the content of Col1a1 in liver tissue, and reducing collagen deposition in liver tissue. Furthermore, the liver-targeted sustained-release drug provided by this invention can reduce the peak plasma concentration of terazosin and prolong its plasma half-life, achieving therapeutic effects equivalent to multiple low-dose injections of terazosin, and has broad application prospects.
Owner:TONGJI HOSPITAL ATTACHED TO TONGJI MEDICAL COLLEGE HUAZHONG SCI TECH
Pharmaceutical formulations
ActiveUS12594243B2Metabolism disorderCarbohydrate active ingredientsExtended release tabletsSGLT2 Inhibitor
The pharmacokinetic profile of the SGLT2 inhibitor bexagliflozin can be improved by formulating it as an extended release tablet. Compared with standard immediate-release dosage forms these tablets can permit a lower peak plasma concentration, Cmax, while maintaining plasma concentrations at therapeutic levels for a desired period. This can be used, for instance, to administer lower doses while still providing the same pharmacological effect.
Owner:THERACOS SUB LLC